Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:    
Net loss $ (13,993) $ (1,927)
Less: loss on discontinued operations, net of taxes (Note 9) (730) (1,864)
Loss from continuing operations (13,263) (63)
Depreciation and amortization 4,165 3,717
Amortization of debt issuance costs 173 221
Deferred tax (benefit) expense (3,062) 418
Recovery of bad debt reserves (314) (433)
Loss (gain) on disposal of plant, property and equipment 2 (80)
Tangible Asset Impairment Charges 1,816
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 8,288
Issuance of common stock for services 238 282
Stock-based compensation 98 92
Changes in operating assets and liabilities of continuing operations:    
Restricted cash 35
Accounts receivable 1,070 (968)
Unbilled receivables 2,134 2,174
Prepaid expenses, inventories and other assets 2,870 41
Accounts payable, accrued expenses and unearned revenue (3,187) (3,657)
Cash provided by continuing operations 1,063 1,744
Cash used in discontinued operations (959) (2,862)
Cash provided by (used in) operating activities 104 (1,118)
Cash flows from investing activities:    
Purchases of property and equipment (436) (623)
Proceeds from sale of property and equipment 44 127
Release of proceeds previously held in escrow from sale of SYA subsidiary in 2014 50
Payments to finite risk sinking fund (107) (46)
Cash used in investing activities of continuing operations (499) (492)
Proceeds from sale of property of discontinued operations 84
Cash used in investing activities (415) (492)
Cash flows from financing activities:    
Borrowing on revolving credit 57,976 67,614
Repayments of revolving credit (56,522) (65,265)
Principal repayments of long term debt (1,508) (2,320)
Principal repayments of long term debt - related party (1,000) (1,500)
Payment of debt issuance costs (122) (40)
Proceeds from issuance of common stock upon exercise of warrants/options 156 10
Proceeds from stock subscription - Perma-Fix Medical S.A. 64 971
Cash used in financing activities of continuing operations (956) (530)
Effect of exchange rate changes on cash (5) (105)
Decrease in cash (1,272) (2,245)
Cash at beginning of period 1,435 3,680
Cash at end of period 163 1,435
Supplemental disclosure:    
Interest paid 424 903
Income taxes paid 41 116
Proceeds from stock subscription for Perma-Fix Medical S.A. held in escrow $ 67